Greenbrook Tms Inc Revenue Growth Rates (GBNH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Greenbrook Tms Inc   (GBNH)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

GBNH's Revenue Growth by Quarter and Year

Greenbrook Tms Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GBNH Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 19.96
1st Quarter March 5.56
FY 25.52





GBNH Revenue second quarter 2024 Y/Y Growth Comment
Greenbrook Tms Inc achieved in the second quarter 2024, above Company average Revenue surge of 211.46% year on year, to $ 19.96 millions.

Looking into second quarter 2024 results within Healthcare Facilities industry 4 other companies have achieved higher Revenue growth. While Greenbrook Tms Inc ' s Revenue doubling of 211.46% ranks overall at the positon no. 853 in the second quarter 2024.


GBNH Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June 211.46 % - - -
1st Quarter March -91.95 % 32.38 % - -
FY   - 218.91 % - -

Financial Statements
Greenbrook Tms Inc 's second quarter 2024 Revenue $ 19.96 millions GBNH's Income Statement
Greenbrook Tms Inc 's second quarter 2023 Revenue $ 6.41 millions Quarterly GBNH's Income Statement


GBNH Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 314.19 % - -
3rd Quarter September - 175.98 % - -
2nd Quarter June 259.07 % -90.72 % - -
1st Quarter March -92.41 % - - -
FY (Year on Year)   - 218.91 % - -


Back to GBNH Growth rate Comparisons >> Back to GBNH Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #219
Overall #853

Revenue Y/Y Growth Statistics
High Average Low
14.03 % -54.02 % -100 %
(Jun 30 2024)   0
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #219
Overall #853
Revenue Y/Y Growth Statistics
High Average Low
14.03 % -54.02 % -100 %
(Jun 30 2024)   0

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Greenbrook Tms Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
14.03 % -54.02 % -100 %
(Jun 30 2024)  


GBNH's II. Quarter Q/Q Revenue Comment
Greenbrook Tms Inc achieved in the II. Quarter 2024 above company average sequential Revenue doubling of 259.07%, to $ 19.96 millions, from $5.56 millions in the first quarter.
GBNH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Greenbrook Tms Inc 's Revenue growth quarter on quarter, overall rank is 853.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #221
Overall #853
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #5
Healthcare Sector #221
Overall #853
Revenue Q/Q Growth Statistics
High Average Low
14.03 % -54.02 % -100 %
(Jun 30 2024)  


GBNH's II. Quarter Q/Q Revenue Comment
Greenbrook Tms Inc achieved in the II. Quarter 2024 above company average sequential Revenue doubling of 259.07%, to $ 19.96 millions, from $5.56 millions in the first quarter.
GBNH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Healthcare Facilities industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Greenbrook Tms Inc 's Revenue growth quarter on quarter, overall rank is 853.


Greenbrook Tms Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 116.49 $ 102.93 $ 166.48 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # 306 # 273 # 377 # 908 # 0
Seqeuential Revenue Change (TTM) 13.16 % -38.17 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 399 # 273 # 377 # 908 # 0


Cumulative Revenue growth Comment
Greenbrook Tms Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 211.46% year on year, to $ 116 millions if the fiscal year would have ended in Jun 30 2024.
Greenbrook Tms Inc 's trailing twelve months Revenue growth was higher than company's average 32.39% and higher than % growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 13.16 % from $102.93 millions achieved in the period from Mar 31 2024 to Mar 31 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at32.39%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 13.16 % increase from $102.93 millions in the period from Mar 31 2024 to Mar 31 2023.

In the Healthcare sector 76 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 273 to 306.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 5
Healthcare Sector # 77
Overall # 306

Revenue TTM Y/Y Growth Statistics
High Average Low
32.39 %
 32.39 %
32.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 127
S&P 500 # 399
Cumulative Revenue growth Comment
Greenbrook Tms Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 211.46% year on year, to $ 116 millions if the fiscal year would have ended in Jun 30 2024.
Greenbrook Tms Inc 's trailing twelve months Revenue growth was higher than company's average 32.39% and higher than % growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 13.16 % from $102.93 millions achieved in the period from Mar 31 2024 to Mar 31 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at32.39%.

In the Healthcare sector 76 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 273 to 306.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 5
Healthcare Sector # 77
Overall # 306

Revenue TTM Y/Y Growth Statistics
High Average Low
32.39 %
32.39 %
32.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 127
S&P 500 # 399




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GBNH's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Generation Bio Co 364.89%$ 364.886 millions
Uniqure N v 359.37%$ 359.372 millions
Tg Therapeutics Inc 357.05%$ 357.049 millions
Cardio Diagnostics Holdings Inc 356.23%$ 356.232 millions
C4 Therapeutics Inc 350.68%$ 350.676 millions
Celularity Inc 312.22%$ 312.219 millions
Spero Therapeutics Inc 275.44%$ 275.442 millions
Molecular Partners Ag271.35%$ 271.345 millions
Siga Technologies Inc271.05%$ 271.049 millions
Biofrontera Inc 260.94%$ 260.944 millions
Sage Therapeutics Inc 249.80%$ 249.798 millions
Inhibrx Biosciences Inc 233.33%$ 233.333 millions
Pavmed Inc 231.00%$ 231.003 millions
Ardelyx inc 227.86%$ 227.865 millions
Lipocine Inc 226.22%$ 226.225 millions
Verve Therapeutics Inc 219.73%$ 219.732 millions
Anaptysbio Inc 217.08%$ 217.081 millions
Nuo Therapeutics Inc 208.69%$ 208.688 millions
Sab Biotherapeutics Inc 207.70%$ 207.698 millions
Esperion Therapeutics Inc 186.33%$ 186.334 millions
Omega Therapeutics Inc 181.16%$ 181.159 millions
Zymeworks Inc 174.82%$ 174.821 millions
Carisma Therapeutics Inc 158.34%$ 158.343 millions
Roivant Sciences Ltd 154.96%$ 154.957 millions
Northwest Biotherapeutics Inc153.73%$ 153.731 millions
Precision Biosciences Inc152.15%$ 152.150 millions
Sutro Biopharma Inc 146.89%$ 146.888 millions
Bioxcel Therapeutics Inc 141.58%$ 141.575 millions
Blueprint Medicines Corporation139.98%$ 139.981 millions
Ocugen Inc 135.26%$ 135.258 millions


About Greenbrook Tms Inc Revenue Growth Rates (GBNH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Greenbrook Tms Inc (CIK 1735948).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-24-089106
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Greenbrook Tms Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.